News Diplomat Pharmacy Chosen to Dispense Ocrevus to MS Patients Across US Diplomat Pharmacy Chosen to Dispense Ocrevus to MS Patients Across US by Patricia Silva, PhD | March 31, 2017 Share this article: Share article via email Copy article link Diplomat Pharmacy, the largest independent specialty pharmacy in the U.S., has been selected to dispenseĀ Ocrevus (ocrelizumab), a limited-distribution drug,Ā to people withĀ relapsingĀ andĀ primary progressive multiple sclerosis. Ocrevus was approved by the U.S. Food and Drug Administration on March 28, becoming the first therapy approved for both RMS and PPMS ā and the first therapy ever indicated as a primary progressive MSĀ treatment. ItĀ was developed by Genentech, a member of the Roche Group, and is expected to be availableĀ by mid-April. “We are excited to make this highly anticipated treatment option available to patients in need,” Paul Urick, Diplomat’s president, said in a press release. “Ocrevus can reduce the burden of multiple sclerosis and give patients hope.” Ocrevus is a monoclonal antibody targeting B-cells (a type of immune cell) that express a protein called CD20 on their surface.Ā CD20-positive B-cells are thought toĀ directly cause damage to the myelin sheath ā an insulating layer allowing signals to pass swiftly through neuronal extensions, known as axons. That damage initiates aĀ series of immune reactions that debilitate MS patients. Studies have shown that Ocrevus binds to B-cells with CD20 markers but not to stem cells or plasma cells, so as toĀ preserveĀ keyĀ immune functions. A story about the development of Ocrevus and its mechanism of action can be found on this link. The treatment is given every six months by intravenous infusion. Relapsing multiple sclerosis is the most common form of this disease, affecting aroundĀ 85 percent of all patients. It is marked by flares, or relapses, defined asĀ the appearance of new symptoms or the return of previous symptoms for 24 hours or more. Patients experience inflammatory attacks on nerve fibers and the myelin sheaths that protect them. Up to 10% of people with MS are diagnosed with primary progressive MS,Ā so named because itĀ progresses from the onset of the first (primary) symptoms.Ā PPMS symptoms steadily worsen over time without relapses or remissions. MS is estimated to affect more than 2.3 million people worldwide, including about 400,000 people in the U.S. Diplomat Pharmacy has a dedicated MS program that can be accessed here. For more information aboutĀ Ocrevus, please visit this link. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags FDA approval, ocrelizumab, Ocrevus, PPMS, RMS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites